Page last updated: 2024-08-25

almagate and Neoplasms

almagate has been researched along with Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lin, JS; Lü, YH; Wang, QZ; Yang, HY; Zhu, Y	1
Becker, RC; Nimjee, SM; Sullenger, BA; White, RR	1
Cavalli, M; Gatto, B	1

Reviews

2 review(s) available for almagate and Neoplasms

Article	Year
[Recent progress of the aptamer-based antiviral drugs]. Yao xue xue bao = Acta pharmaceutica Sinica, 2013, Volume: 48, Issue:4 Topics: Antiviral Agents; Aptamers, Nucleotide; Genome, Viral; Hepacivirus; HIV; HIV Reverse Transcriptase; Humans; Macular Degeneration; Neoplasms; Oligodeoxyribonucleotides; RNA, Small Interfering; SELEX Aptamer Technique; Viral Envelope Proteins; Virus Replication	2013
Aptamers as Therapeutics. Annual review of pharmacology and toxicology, 2017, 01-06, Volume: 57 Topics: Animals; Aptamers, Nucleotide; Humans; Neoplasms; Randomized Controlled Trials as Topic; SELEX Aptamer Technique; Vision Disorders	2017

Other Studies

1 other study(ies) available for almagate and Neoplasms

Article	Year
From proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapy. Anti-cancer agents in medicinal chemistry, 2006, Volume: 6, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Controlled Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Protein Engineering; Ranibizumab; RNA, Small Interfering; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors	2006

Article

Year

From proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapy.

Anti-cancer agents in medicinal chemistry, 2006, Volume: 6, Issue:4

Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Controlled Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Protein Engineering; Ranibizumab; RNA, Small Interfering; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors

2006